These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7516602)

  • 1. The value of prostatic specific antigen in prostate cancer screening in the community.
    Jubelirer SJ; Tierney JP; Oliver S; Serrato JM; Farra S; Plymale J; Hodge E
    W V Med J; 1994 Apr; 90(4):140-2. PubMed ID: 7516602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Screening of cancer of the prostate: study in a Spanish population].
    Herrero Payo JA; Montes Díaz MJ; Páez Borda A; Sánchez Sánchez E; Moreno Valle JA; Berenguer Sánchez A
    Arch Esp Urol; 1996; 49(6):595-606. PubMed ID: 8929102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey.
    Bunker CH; Patrick AL; Konety BR; Dhir R; Brufsky AM; Vivas CA; Becich MJ; Trump DL; Kuller LH
    Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):726-9. PubMed ID: 12163325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of digital rectal examination on serum prostate-specific antigen in a primary care setting. The Internal Medicine Clinic Research Consortium.
    Arch Intern Med; 1995 Feb; 155(4):389-92. PubMed ID: 7531426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of prostate cancer detected by digital rectal examination only.
    Okotie OT; Roehl KA; Han M; Loeb S; Gashti SN; Catalona WJ
    Urology; 2007 Dec; 70(6):1117-20. PubMed ID: 18158030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study on the prevalence of clinically detectable prostate cancer in patients with and without bladder cancer.
    Kurokawa K; Ito K; Yamamoto T; Takechi H; Miyamoto S; Suzuki K; Yamanaka H
    Urology; 2004 Feb; 63(2):268-72. PubMed ID: 14972469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).
    Roobol MJ; Zappa M; Määttänen L; Ciatto S
    Prostate; 2007 Mar; 67(4):439-46. PubMed ID: 17192912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digital rectal examination is barrier to population-based prostate cancer screening.
    Nagler HM; Gerber EW; Homel P; Wagner JR; Norton J; Lebovitch S; Phillips JL
    Urology; 2005 Jun; 65(6):1137-40. PubMed ID: 15922431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of prostate cancer screening in Thai elderly.
    Tantiwong A; Soontrapa S; Sujijantrarat P; Vanprapar N; Sawangsak L
    J Med Assoc Thai; 2002 Apr; 85(4):502-8. PubMed ID: 12118499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
    Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
    Ito K; Kubota Y; Yamamoto T; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
    Cancer; 2001 Feb; 91(4):744-51. PubMed ID: 11241242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing level of prostate-specific antigen and prostate cancer risk factors among 193 men examined in screening procedure.
    Opalińska E; Michalak A; Stoma F; Latalski M; Goniewicz M
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):57-63. PubMed ID: 15323167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen.
    Labrie F; Candas B; Cusan L; Gomez JL; Diamond P; Suburu R; Lemay M
    Urology; 1996 Feb; 47(2):212-7. PubMed ID: 8607237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
    J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer.
    Galić J; Karner I; Cenan L; Tucak A; Hegedus I; Pasini J; Bilandzija-Peranović M; Mihaljević S
    Coll Antropol; 2003; 27 Suppl 1():61-6. PubMed ID: 12955893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.